DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ditropan (Oxybutynin Chloride) - Summary

 
 



DITROPAN SUMMARY

DITROPAN XL® (oxybutynin chloride) is an antispasmodic, anticholinergic agent. Each DITROPAN XL® Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers.

DITROPAN XL® (oxybutynin chloride) is a once-daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

DITROPAN XL® is also indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).


See all Ditropan indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Ditropan (Oxybutynin)

A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. [2014]
vaginal ring in women with overactive bladder... CONCLUSIONS: The oxybutynin vaginal ring appears to be an effective and safe once

Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors. [2012]
evaluated... CONCLUSIONS: Our findings highlight that anticholinergic agents may play an

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011.11]
OBJECTIVES: To determine the efficacy of oral extended-release oxybutynin for urge urinary incontinence in older female nursing home residents with mild to severe cognitive impairment... CONCLUSION: Extended-release oxybutynin 5 mg per day for 4 weeks in older cognitively impaired female nursing home residents did not significantly reduce urinary incontinence and urinary frequency or achieve dryness. Participants with mild to moderate cognitive and/or physical impairment were no more likely to benefit from oxybutynin than more severely impaired individuals in an exploratory analysis but further research in a larger population and perhaps using a larger dose is needed. Copyright (c) 2011 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.

Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. [2011.02]
CONCLUSIONS: Solifenacin 5 mg/day was better tolerated than oxybutynin IR 15 mg/day in younger (</= 65 years) and older (> 65 years) subgroups. Solifenacin was equally well tolerated in both age subgroups. Limitations of the analysis were that the study was not preplanned to perform post-hoc subgroup analysis, patients knew that dry mouth was a primary outcome, and the study used fixed doses of each drug.

[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [2011.01]
OBJECTIVE: To compare the efficacy and safety of tolterodine and oxybutynin in the treatment of idiopathic overactive bladder in children... CONCLUSIONS: Tolterodine has a similar efficacy to oxybutynin in the treatment of idiopathic overactive bladder in children, with better safety in pharmacotherapy.

more studies >>

Clinical Trials Related to Ditropan (Oxybutynin)

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER [Recruiting]
Overactive bladder is a condition associated with symptoms of feeling the urge to urinate, urinating often, and may or may not be accompanied by leakage of urine. A patient who has a spinal cord injury (SCI) often suffers from an overactive bladder which often leads to

urinary incontinence (UI - an unwanted leakage of urine).

OnaBoNT-A bladder injections have been studied in clinical research trials. The results have shown an improvement in urinary symptoms by reducing how often urine leakage occurs and by increasing the amount of urine the bladder can hold. This purpose of this clinical trial is to see if onaBoNT-A is safe and effective when injected into the bladder for the treatment of UI and if it works better than a drug that is taken by mouth. A second purpose of the study is to perform research tests on the urine samples provided by the volunteers. Urine presents a rich source of information for bladder diseases and the biomarkers (the chemical make-up of the urine cells) will be examined to learn if there are yet undiscovered reasons for urinary diseases. These tests would be very beneficial because the results would lead to better treatment of the urinary diseases. Volunteers will be randomized to either: ARM 1: onaBoNT-A 200 U bladder injection and placebo oral capsule daily or ARM 2: Placebo bladder injection (saline) and oxybutynin ER 15mg capsule daily. The treatments are onaBoNT-A bladder injection and a placebo oral capsule once a day or placebo bladder injection and oxybutynin ER (like Ditropan) capsule once a day. Placebo contains no active medicine. Participation in this study will be about 6-7 months and involve 5 visits to the clinic. The risks of bladder onaBoNT-A

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children [Enrolling by invitation]

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED) [Completed]
This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.

Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study [Completed]
Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.

Treatment of Hyperhidrosis With Oxybutynin [Completed]

more trials >>

Reports of Suspected Ditropan (Oxybutynin) Side Effects

Confusional State (6)Cognitive Disorder (5)Parkinsonism (4)Leukoencephalopathy (4)Iatrogenic Injury (4)Cerebral Atrophy (4)Fall (3)Dizziness (3)Convulsion (3)Tremor (3)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 3 ratings/reviews, Ditropan has an overall score of 4.33. The effectiveness score is 6.67 and the side effect score is 5.33. The scores are on ten point scale: 10 - best, 1 - worst.
 

Ditropan review by care giver of 6 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   incontinence
Dosage & duration:   2x 5ml daily (dosage frequency: 2x daily) for the period of 1 month
Other conditions:   urge incontinence, wetting at night
Other drugs taken:   n/a
  
Reported Results
Benefits:   The medicine has stopped her wetting both day and night and worked within a week of her taking it. She is over the moon and so am I!
Side effects:   My daughter complains of a pain in her bladder area and some constipation and her face looks a little flushed. I am considering lowering the dose to 2x 2.5ml per day
Comments:   She has had 4 years of bladder infections and has had various scans and tests. I think that she has never been able to read the signals from her bladder properly due to all the infections. This medicine which was prescribed by the dr on a trial basis seems to be working well. We will try to wean her off it slowly after a little while

 

Ditropan review by 25 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   Hyperhidrosis
Dosage & duration:   1 pill 3 times a day taken every day for the period of around 2 years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   stopped sweating, but the drying effect brought a very dry mouth and throat as well as side effect
Side effects:   very dry thoat and eyes, dry mouth, burning sensation when urinating.
Comments:   the drug is not to treat hyperhidrosis, but it's its side effects that the drug was being taken for - namely the drying up for hyperhidrosis

 

Ditropan review by 25 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   Hyperhidrosis
Dosage & duration:   1 pill 3 times a day taken every day for the period of around 2 years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   stopped sweating, but the drying effect brought a very dry mouth and throat as well as side effect
Side effects:   very dry thoat and eyes, dry mouth, burning sensation when urinating.
Comments:   the drug is not to treat hyperhidrosis, but it's its side effects that the drug was being taken for - namely the drying up for hyperhidrosis

See all Ditropan reviews / ratings >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017